|Issue Date||06/12 - 08/12|
|Issue Size||₹300.0 Cr|
|Issue Price||₹426 - 428|
|Market Lot||35 Shares|
|Shares on Offer||24,107,440|
|Subject to Sauda||N/A|
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus Labs also manufactures APIs in oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Out of Ten largest generic pharmaceutical companies in the world, by revenues, are their customers.
They believe that their significant investment in enhancing their manufacturing capabilities has also resulted in economies of scale and helped us in consistently gaining market share in an expanding market for their key ARV APIs. Their manufacturing facilities have received one or more approvals from WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM.
Their manufacturing facilities are capable of large scale commercial production of APIs enabling us to position ourselves as suppliers of choice for pharmaceutical companies seeking to leverage their technical expertise, cost effective manufacturing and capacities. They are further building on their API strength to forward integrate into Fixed Dosage Formulation (FDF)
With an investment of INR 2013.66 million, as of March 31, 2016, Laurus Labs is building a FDF manufacturing facility with a capacity of one billion tablets per year expandable 5 billion tablets for year after incurring additional investment.
They leverage their strong process chemistry skills to provide synthesis services. As part of their synthesis business, they work with global pharmaceutical companies for providing analytical and research services, clinical research supplies and commercial scale contract manufacturing services. The services offered under their Synthesis business include Alternate Route development, process development, process optimization and validation, scale up of clinical phase new chemical entities, and commercial manufacturing.
They are focused on undertaking dedicated R&D in areas that have significant growth potential. Their systematic approach to selection of molecules, which involves evaluation of technical and commercial feasibility data, and customer feedback has resulted in commercialization of 30 out of the 37 filed DMFs. In addition, as of September 30, 2016, they own 34 patents and have 152 pending applications in several countries and 59 products have been commercialised since their inceptio
They also develop and manufacture speciality ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. During the financial year 2016, they sold their APIs in 32 countries.
|Total Assets (In ₹ Millions)||23,083.48||18,925.49||12,730.58||7,009.89||5,128.78|
|Total Revenue (In ₹ Millions)||17,884.15||13,603.80||11,685.34||7,235.67||4,523.07|
|Profit After Tax (PAT) (In ₹ Millions)||1,435.68||735.17||972.17||882.19||215.77|
|Date & Time||QIB||NII||RII||Total|
|Day 1 - Dec 06,2016||0.71||0.16||0.10||0.28|
|Day 2 - Dec 07,2016||1.02||0.54||0.39||0.61|
|Day 3 - Dec 08,2016||10.54||3.57||1.58||4.53|
Please click the link below to check the IPO allotment status.IPO Allotment Status
Laurus Labs Ltd IPO IPO will open on 06/12 and close on 08/12.
Laurus Labs Ltd IPO IPO will list on 19-Dec.
The offer price of Laurus Labs Ltd IPO IPO is ₹426 - 428.
The lot size of Laurus Labs Ltd IPO IPO is 35.
The Grey Market Premium (GMP) price of Laurus Labs Ltd IPO IPO is Not Available at the moment.
The Kostak price of Laurus Labs Ltd IPO IPO is Not Available at the moment.
The Subject to Sauda price for Laurus Labs Ltd IPO IPO is Not Available at the moment.
Please Leave Your Message